Myrexis

Myrexis is a biopharmaceutical company based in Salt Lake City, Utah, USA.

It focused on drug development in several areas of medicine, in particular cancer therapy and auto-immune diseases.

[2][3] In February 2012 the company announced they had suspended development activity on all of its clinical and preclinical programs and appointed an investment company Stifel Nicolaus Weisel to evaluate strategic alternatives.

[4] In November 2012, the board of Myrexis announced that it planned to put the company into liquidation subject to shareholder approval.

[5] In January 2013, the board reversed its decision, cancelled the liquidation, declared a special cash distribution to shareholders and appointed Jonathan M. Couchman (chairman of Xselos Holdings) as president and chief executive officer.